Prosthetic Heart Valves, Part I: Identification and Potential Complications

Jagdish Butany, MBBS, MS, FRCPC; Gursharan S. Soor, BSc; Moyukh Chakrabarti, BSc; Iva Vukin, BSc; Shaun W. Leong, BSc


Geriatrics and Aging. 2006;9(10):691-696. 

In This Article

Biological Heart Valves ( Table 3 )

The Carpentier-Edwards Supraanular® (CE SAV) bioprosthesis has two models, the 2650 (aortic) and 6650 (mitral). This valve has a long and successful history. The porcine aortic valve used in the CE SAV bioprosthesis is processed using the XenoLogiX treatment to mitigate calcium enucleation in the porcine tissue. The standard model of this valve at times had an unusual mode of failure, with separation of the aortic commissural region at the suture line, leading to cusp prolapse and prosthesis incompetence.[27]

The CE SAV® has a low incidence of structural valve deterioration and has good clinical performance.[25] At 18 years, CE SAV bioprostheses have maintained an actuarial freedom from structural valve deterioration of 94.6% in patients greater than 70 years of age with a cumulative risk of explant due to structural valve deterioration of only 1.8%.[25] Freedom from valve-related complications at five years has been reported at 84.1% ± 1.3%.[1,26]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.